Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Merck & company, inc. crawled time : 12:20 save search
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Published: 2023-06-01 (Crawled : 12:20) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.23%
H: 0.84%
C: 0.24%
lynparza fda cancer treatment plus
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
Published: 2023-04-16 (Crawled : 12:20) - globenewswire.com
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
| Email alert
Add to watchlist
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
merck pipeline acquisition immunology
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma
Published: 2023-03-10 (Crawled : 12:20) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.15%
H: 3.05%
C: 0.23%
keytruda treatment plus
US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII, VARIVAX and ProQuad
Published: 2023-03-06 (Crawled : 12:20) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.73%
H: 3.33%
C: 3.2%
fda
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
Published: 2023-01-11 (Crawled : 12:20) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -1.33%
H: 1.8%
C: 1.58%
acquire
Merck to Present at the 41st Annual J.P. Morgan Healthcare Conference
Published: 2023-01-03 (Crawled : 12:20) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.49%
H: 0.72%
C: 0.66%
conference
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® with KEYTRUDA® for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
Published: 2022-12-20 (Crawled : 12:20) - biospace.com/
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 1.66%
H: 1.12%
C: 0.03%
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.46%
H: 0.65%
C: -0.21%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.0%
H: 4.57%
C: 4.22%
padcev treatment fda cancer
AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate Cancer
Published: 2022-12-15 (Crawled : 12:20) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -1.17%
H: 0.48%
C: -0.55%
lynparza treatment review update cancer prostate cancer
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Published: 2022-12-13 (Crawled : 12:20) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 2.1%
H: 0.0%
C: -0.31%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 13.44%
H: 11.31%
C: 5.45%
rna-4157 mrna trial cancer phase 2b
Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Published: 2022-11-22 (Crawled : 12:20) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.49%
H: 0.92%
C: 0.73%
ynote-859 trial her2- her2
U.S. District Court Rules In Favor of Merck in Sitagliptin Phosphate Patent Lawsuit
Published: 2022-09-22 (Crawled : 12:20) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.02%
H: 4.26%
C: 3.5%
patent
Organon Reports Results for the First Quarter Ended March 31, 2022
Published: 2022-05-05 (Crawled : 12:20) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 1.98%
H: 0.27%
C: -0.46%
Organon To Report First Quarter Results and Host Conference Call on May 5, 2022
Published: 2022-04-21 (Crawled : 12:20) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 1.01%
H: 0.0%
C: 0.0%
conference report results
Health Canada Approves GARDASIL (Human Papillomavirus 9-valent Vaccine, Recombinant) for the Prevention of Oropharyngeal and Other Head and Neck Cancers
Published: 2022-04-11 (Crawled : 12:20) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.73%
H: 1.31%
C: -1.91%
canada health
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.